Dicerna Pharmaceuticals Inc (DRNA) Stock Price, Forecast & Analysis
USA - NASDAQ:DRNA - Common Stock
DRNA Key Statistics, Chart & Performance
The current stock price of DRNA is 38.22 null. In the past month the price increased by 0.61%. In the past year, price increased by 73.49%.
DRNA Latest News, Press Relases and Analysis
DRNA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.59 | 410.48B | ||
| AMGN | AMGEN INC | 15.4 | 181.29B | ||
| GILD | GILEAD SCIENCES INC | 15.26 | 155.13B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.18 | 112.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.41 | 73.50B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 880.71 | 58.88B | ||
| INSM | INSMED INC | N/A | 40.84B | ||
| NTRA | NATERA INC | N/A | 28.04B | ||
| BIIB | BIOGEN INC | 10.01 | 24.56B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.67 | 21.10B | ||
| INCY | INCYTE CORP | 16.22 | 20.34B | ||
| NBIX | NEUROCRINE BIOSCIENCES INC | 34.66 | 14.37B |
Related stock screener links
About DRNA
Company Profile
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The company is headquartered in Lexington, Massachusetts and currently employs 302 full-time employees. The company went IPO on 2014-01-30. The firm is focused on discovering, developing, and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. The firm's GalXC RNAi technology Platform consists of its liver-targeted GalXC technology and GalXC-Plus technology for tissues outside the liver. The firm's product line includes nedosiran, RG6346, belcesiran, and DCR-AUD. Its lead product candiadate nedosiran is a RNAi drug candidate developed for the treatment of hyperoxaluria (PH). The RG6346 for the treatment of chronic hepatitis B virus (HBV) infection. The belcesiran for the treatment of alpha-1 antitrypsin deficiency-associated liver disease (AATLD). The DCR-AUD for the treatment of alcohol use disorder (AUD).
Company Info
Dicerna Pharmaceuticals Inc
75 Hayden Avenue
Lexington MASSACHUSETTS 02421 US
CEO: Douglas M. Fambrough
Employees: 302
Phone: 16176218097.0
Dicerna Pharmaceuticals Inc / DRNA FAQ
What does DRNA do?
Dicerna Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in discovering, developing and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to selectively silence genes that cause or contribute to disease. The company is headquartered in Lexington, Massachusetts and currently employs 302 full-time employees. The company went IPO on 2014-01-30. The firm is focused on discovering, developing, and commercializing medicines that are designed to leverage ribonucleic acid interference (RNAi) to silence selectively genes that cause or contribute to disease. The firm's GalXC RNAi technology Platform consists of its liver-targeted GalXC technology and GalXC-Plus technology for tissues outside the liver. The firm's product line includes nedosiran, RG6346, belcesiran, and DCR-AUD. Its lead product candiadate nedosiran is a RNAi drug candidate developed for the treatment of hyperoxaluria (PH). The RG6346 for the treatment of chronic hepatitis B virus (HBV) infection. The belcesiran for the treatment of alpha-1 antitrypsin deficiency-associated liver disease (AATLD). The DCR-AUD for the treatment of alcohol use disorder (AUD).
What is the current price of DRNA stock?
The current stock price of DRNA is 38.22 null. The price increased by 0.58% in the last trading session.
Does Dicerna Pharmaceuticals Inc pay dividends?
DRNA does not pay a dividend.
What is the ChartMill technical and fundamental rating of DRNA stock?
DRNA has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Would investing in Dicerna Pharmaceuticals Inc be a good decision?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on DRNA.
What is the expected growth for DRNA stock?
The Revenue of Dicerna Pharmaceuticals Inc (DRNA) is expected to decline by -6.12% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
Who owns Dicerna Pharmaceuticals Inc?
You can find the ownership structure of Dicerna Pharmaceuticals Inc (DRNA) on the Ownership tab.
DRNA Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to DRNA. When comparing the yearly performance of all stocks, DRNA is one of the better performing stocks in the market, outperforming 98.23% of all stocks.
DRNA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to DRNA. Both the profitability and the financial health of DRNA get a neutral evaluation. Nothing too spectacular is happening here.
DRNA Financial Highlights
Over the last trailing twelve months DRNA reported a non-GAAP Earnings per Share(EPS) of -1.63. The EPS decreased by -1.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -64.53% | ||
| ROA | -16.12% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |
DRNA Forecast & Estimates
14 analysts have analysed DRNA and the average price target is 37.16 null. This implies a price decrease of -2.78% is expected in the next year compared to the current price of 38.22.
For the next year, analysts expect an EPS growth of -13.03% and a revenue growth -6.12% for DRNA